Score Overview
Explore the 2021 public Archive ranking →
Where Alnylam Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ALNY
2015: 94.1% · 2021: 95.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 255.36 | — |
1 Year2025-09-26 | $ 446.40 | -42.80% |
5 Years2021-09-28 | $ 177.08 | 44.21% |
10 Years2016-09-28 | $ 76.67 | 233.06% |
20 Years2006-09-28 | $ 14.48 | 17x |
All Time2004-05-28 | $ 6.01 | 42x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | All Time2004-05-28 |
|---|---|---|---|---|---|---|
| Price | $ 255.36 | $ 446.40 | $ 177.08 | $ 76.67 | $ 14.48 | $ 6.01 |
| Return | — | -42.80% | 44.21% | 233.06% | 17x | 42x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 4.80B | $ 807M | $ 3.30B |
| 2025 | $ 3.71B | $ 313M | $ 2.90B |
| 2024 | $ 2.24B | -$ 278M | $ 2.69B |
| 2023 | $ 1.82B | -$ 440M | $ 2.43B |
| 2022 | $ 1.03B | -$ 1.13B | $ 2.19B |
| 2021 | $ 844M | -$ 852M | $ 2.43B |
| 2020 | $ 492M | -$ 858M | $ 1.87B |
| 2019 | $ 219M | -$ 886M | $ 1.53B |
| 2018 | $ 74M | -$ 761M | $ 1.08B |
| 2017 | $ 89M | -$ 490M | $ 1.70B |
| 2016 | $ 47M | -$ 410M | $ 942M |
| 2015 | $ 41M | -$ 290M | $ 1.08B |
| 2014 | $ 50M | -$ 360M | $ 696M |
| 2013 | $ 47M | -$ 89M | $ 245M |
| 2012 | $ 66M | -$ 106M | $ 122M |
| 2011 | $ 82M | -$ 57M | $ 146M |
| 2010 | $ 100M | -$ 43M | $ 233M |
| 2009 | $ 100M | -$ 47M | $ 281M |
| 2008 | $ 96M | -$ 26M | $ 430M |
| 2007 | $ 50M | -$ 85M | $ 389M |
| 2006 | $ 26M | -$ 34M | $ 217M |
| 2005 | $ 5M | -$ 42M | $ 80M |
| IPO2004 | $ 4M | -$ 32M | $ 46M |
Alnylam Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 492M to $ 3.71B and net income went from -$ 858M to $ 313M. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 41M to $ 3.71B and net income went from -$ 290M to $ 313M. Revenue increased in 9 of those 10 years; net income in 6.
Alnylam Pharmaceuticals Inc currently holds a 20-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.
Membership
Continue ALNY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
